Decreased plasma endogenous soluble RAGE, and enhanced adipokine secretion, oxidative stress and platelet/coagulative activation identify non-alcoholic fatty liver disease among patients with familial combined hyperlipidemia and/or metabolic syndrome

Vascular Pharmacology

Volumn 72, Issue , 2015, Pages 16-24

  Santilli, Francesca ^a   Blardi, Patrizia ^b   Scapellato, Carlo ^c   Bocchia, Monica ^b   Guazzi, Gianni ^c   Terzuoli, Lucia ^c   Tabucchi, Antonella ^c   Silvietti, Antonella ^c   Lucani, Benedetta ^b   Gioffrè, Walter Renato ^b   Scarpini, Francesca ^b   Fazio, Francesca ^a   Davì, Giovanni ^a   Puccetti, Luca ^b  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

Atherothrombosis; CD40 CD40L; esRAGE; FCHL; Metabolic syndrome; NAFLD

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN A; APOLIPOPROTEIN B; C REACTIVE PROTEIN; CD40 LIGAND; GAMMA GLUTAMYLTRANSFERASE; INSULIN; INTERLEUKIN 10; INTERLEUKIN 6; LEPTIN; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; THROMBIN; TUMOR NECROSIS FACTOR ALPHA; IL10 PROTEIN, HUMAN; LOW DENSITY LIPOPROTEIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYTOKINE RELEASE; DIASTOLIC BLOOD PRESSURE; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FAMILIAL HYPERLIPEMIA; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INVASIVE PROCEDURE; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; WAIST CIRCUMFERENCE; BLOOD CLOTTING; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; THROMBOCYTE; THROMBOCYTE ACTIVATION;

ADIPOKINES; ADIPONECTIN; ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; BLOOD COAGULATION; BLOOD PLATELETS; CD40 LIGAND; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERLIPIDEMIA, FAMILIAL COMBINED; INTERLEUKIN-10; LIPOPROTEINS, LDL; LONGITUDINAL STUDIES; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS; PLATELET ACTIVATION; THROMBIN;

EID: 84939569728     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2015.04.004     Document Type: Article

References (48)

1. Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 2002, 346:1221-1231.
2. Fabbrini E., Sullivan S., Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 2010, 51:679-689.
3. Chalasani N., Younossi Z., Lavine J.E., Diehl A.M., Brunt E.M., Cusi K., Charlton M., Sanyal A.J., American Gastroenterological Association, American Association for the Study of Liver Diseases, American College of Gastroenterology The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012, 142:1592-1609.
4. Kotronen A., Westerbacka J., Bergholm R., Pietiläinen K.H., Yki-Järvinen H. Liver fat in the metabolic syndrome. J. Clin. Endocrinol. Metab. 2007, 92:3490-3497.
5. Targher G., Day C.P., Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N. Engl. J. Med. 2010, 363:1341-1350.
6. Targher G., Byrne C.D. Nonalcoholic Fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. J. Clin. Endocrinol. Metab. 2013, 98:483-495.
7. Kim H.J., Kim H.J., Lee K.E., Kim D.J., Kim S.K., Ahn C.W., Lim S.K., Kim K.R., Lee H.C., Huh K.B., Cha B.S. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch. Intern. Med. 2004, 164:2169-2175.
8. Shoulders C.C., Jones E.L., Naoumova R.P. Genetics of familial combined hyperlipidemia and risk of coronary heart disease. Hum. Mol. Genet. 2004, 13:R149-R160.
9. Santilli F., Blardi P., Scarpini F., Acciavatti A., Ceccatelli L., Magliocca A., Avolio T., Bocchia M., Scapellato C., Gioffrè W.R., Auteri A., Ferracane S.C., Puccetti L. Genetic influence in liver steatosis prevalence and proatherothrombotic/inflammatory profile in familial combined hyperlipoproteinemia. Int. J. Cardiol. 2013, 168:536-539.
10. Hyogo H., Yamagishi S. Advanced glycation end products (AGEs) and their involvement in liver disease. Curr. Pharm. Des. 2008, 14:969-972.
11. Santilli F., Vazzana N., Bucciarelli L.G., Davì G. Soluble forms of RAGE in human diseases: clinical and therapeutical implications. Curr. Med. Chem. 2009, 16:940-952.
12. Yan S.F., Ramasamy R., Schmidt A.M. Receptor for AGE (RAGE) and its ligands - cast into leading roles in diabetes and the inflammatory response. J. Mol. Med. 2009, 87:235-247.
13. Basta G., Navarra T., De Simone P., Del Turco S., Gastaldelli A., Filipponi F. What is the role of the receptor for advanced glycation end products-ligand axis in liver injury?. Liver Transpl. 2011, 17:633-640.
14. Koyama H., Shoji T., Yokoyama H., et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2005, 25:2587-2593.
15. Selvin E., Halushka M., Rawlings A., Hoogeveen R.C., Ballantyne C.M., Coresh J., et al. sRAGE and risk of diabetes, cardiovascular disease and death. Diabetes 2013, 62:2116-2121.
16. Yilmaz Y., Ulukaya E., Gul O.O., Arabul M., Gul C.B., Atug O., Oral A.Y., Aker S., Dolar E. Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease. Clin. Biochem. 2009, 42:802-807.
17. Veerkamp M.J., de Graaf J., Bredie S.J., Hendriks J.C., Demacker P.N., Stalenhoef A.F. Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: results of a 5-year follow-up study. Arterioscler. Thromb. Vasc. Biol. 2002, 22:274-282.
18. Ayyobi A.F., McGladdery S.H., McNeely M.J., Austin M.A., Motulsky A.G., Brunzell J.D. Small, dense LDL and elevated apolipoprotein B are the common characteristics for the three major lipid phenotypes of familial combined hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 2003, 23:1289-1294.
19. 2014 Evidence-based guideline for the management of high blood pressure in adults. Report from the Panel Members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014, 311(5):507-520.
20. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2003, 287:356-359.
21. Riggio S., Mamone F., Mandraffino G., Maimone S., Alibrandi A., Manti L., Saitta C., Tripodi P.F., Sardo M.A., Squadrito G., Saitta A. Assessment of liver stiffness in subjects affected by familial combined hyperlipidaemia with hepatic steatosis. Eur. J. Clin. Invest. 2010, 40:722-728.
22. Matthews D., Hosker J., Rudenski A. Homeostasis model assessment: insulin resistance and cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
23. Bedogni G., Bellentani S., Miglioli L., Masutti F., Passalacqua M., Castiglione A., Tiribelli C. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006, 6:33.
24. Puccetti L., Santilli F., Pasqui A.L., Lattanzio S., Liani R., Ciani F., Ferrante E., Ciabattoni G., Scarpini F., Ghezzi A., Auteri A., Davì G. Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia. Atherosclerosis 2011, 214:122-128.
25. Ferrante E., Vazzana N., Santilli F., Di Cicco M., Lauriti C., Di Battista L., Ciabattoni G., Di Matteo L., Davì G. Determinants of thromboxane biosynthesis in rheumatoid arthritis: role of RAGE and oxidant stress. Free Radic. Biol. Med. 2010, 49:857-864.
26. Eichinger S., Hron G., Kollars M., Kyrle P.A. Prediction of recurrent venous thromboembolism by endogenous thrombin potential and d-dimer. Clin. Chem. 2008, 54:2042-2208.
27. Riondino S., Martini F., La Farina F., Spila A., Guadagni F., Ferroni P. Increased plasma levels of soluble CD40 ligand correlate with platelet activation markers and underline the need for standardized pre-analytical conditions. Clin. Biochem. 2010, 43:666-670.
28. Puccetti L., Pasqui A.L., Pastorelli M., Ciani F., Palazzuoli A., Gioffrè W., Auteri A., Bruni F. 3'UTR/T polymorphism of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is associated with modified anti-platelet activity of atorvastatin in hypercholesterolemic subjects. Atherosclerosis 2007, 183:322-328.
29. Chen Q., Reis S.E., Kammerer C., Craig W.Y., LaPierre S.E., Zimmer E.L., McNamara D.M., Pauly D.F., Sharaf B., Holubkov R., Bairey Merz C.N., Sopko G., Bontempo F., Kamboh M.I. Genetic variation in lectin-like oxidized low-density lipoprotein receptor 1 (LOX1) gene and the risk of coronary artery disease. Circulation 2003, 107:3146-3151.
30. Puccetti L., Bruni F., Pasqui A.L., Pastorelli M., Ciani F., Palazzuoli A., Acampa M., Auteri A. Genetic influence in antithrombotic actions of atorvastatin in hypercholesterolaemia. Eur. J. Clin. Invest. 2008, 38:11-16.
31. Pasqui A.L., Di Renzo M., Auteri A., Puccetti L. Cytokines in acute coronary syndromes. Int. J. Cardiol. 2005, 105:355-356.
32. Pasqui A.L., Di Renzo M., Bova G., Maffei S., Pompella G., Auteri A., Puccetti L. Pro-inflammatory/anti-inflammatory cytokine imbalance in acute coronary syndromes. Clin. Exp. Med. 2006, 6:38-44.
33. Predazzi I.M., Martínez-Labarga C., Vecchione L., Mango R., Ciccacci C., Amati F., Ottoni C., Crawford M.H., Rickards O., Romeo F., Novelli G. Population differences in allele frequencies at the OLR1 locus may suggest geographic disparities in cardiovascular risk events. Ann. Hum. Biol. 2010, 37:137-149.
34. Poli F., Nocco A., Berra S., Scalamogna M., Taioli E., Longhi E., Sirchia G. Allele frequencies of polymorphisms of TNFA, IL-6, IL-10 and IFNG in an Italian Caucasian population. Eur. J. Immunogenet. 2002, 29:237-240.
35. Chiodini B.D., Specchia C., Gori F., Barlera S., D'Orazio A., Pietri S., Crociati L., Nicolucci A., Franciosi M., Signorini S., Brambilla P., Grazia Franzosi M., GISSI Prevenzione Investigators, SiBioC-GISSI Prevenzione Group Adiponectin gene polymorphisms and their effect on the risk of myocardial infarction and type 2 diabetes: an association study in an Italian population. Ther. Adv. Cardiovasc. Dis. 2010, 4:223-230.
36. Puccetti L., Ciani F., Auteri A. Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study. Atherosclerosis 2010, 211:28-29.
37. Bhatia L.S., Curzen N.P., Calder P.C., Byrne C.D. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?. Eur. Heart J. 2012, 33:1190-1200.
38. Gaens K.H., Niessen P.M., Rensen S.S., Buurman W.A., Greve J.W., Driessen A., Wolfs M.G., Hofker M.H., Bloemen J.G., Dejong C.H., Stehouwer C.D., Schalkwijk C.G. Endogenous formation of Nε-(carboxymethyl)lysine is increased in fatty livers and induces inflammatory markers in an in vitro model of hepatic steatosis. J. Hepatol. 2012, 56:647-655.
39. Leung C., Herath C.B., Jia Z., Goodwin M., Mak K.Y., Watt M.J., Forbes J.M., Angus P.W. Dietary glycotoxins exacerbate progression of experimental fatty liver disease. J. Hepatol. 2014, 60:832-838.
40. Day C.P., James O.F. Steatohepatitis: a tale of two "hits"?. Gastroenterology 1998, 114:842-845.
41. D'Adamo E., Giannini C., Chiavaroli V., de Giorgis T., Verrotti A., Chiarelli F., Mohn A. What is the significance of soluble and endogenous secretory receptor for advanced glycation end products in liver steatosis in obese prepubertal children?. Antioxid. Redox Signal. 2011, 14:1167-1172.
42. Momma H., Niu K., Kobayashi Y., Huang C., Chujo M., Otomo A., Tadaura H., Miyata T., Nagatomi R. Lower serum endogenous secretory receptor for advanced glycation end product level as a risk factor of metabolic syndrome among Japanese adult men: a 2-year longitudinal study. J. Clin. Endocrinol. Metab. 2014, 99:587-593.
43. Sun L., Ishida T., Yasuda T., Kojima Y., Honjo T., Yamamoto Y., Ishibashi S., Hirata K., Hayashi Y. RAGE mediates oxidized LDL-induced pro-inflammatory effects and atherosclerosis in non-diabetic LDL receptor-deficient mice. Cardiovasc. Res. 2009, 82:371-381.
44. Feng B., Xu L., Wang H., Yan X., Xue J., Liu F., Hu J.F. Atorvastatin exerts its anti-atherosclerotic effects by targeting the receptor for advanced glycation end products. Biochim. Biophys. Acta 1812, 2011:1130-1137.
45. Santilli F., Bucciarelli L., Noto D., Cefalù A.B., Davì V., Ferrante E., Pettinella C., Averna M.R., Ciabattoni G., Davì G. Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. Free Radic. Biol. Med. 2007, 43:1255-1262.
46. Ahmed M.H., Barakat S., Almobarak A.O. Nonalcoholic fatty liver disease and cardiovascular disease: has the time come for cardiologists to be hepatologists?. J. Obes. 2012, 483135.
47. Mehta S.R., Godsland I.F., Thomas E.L., Pavitt D.V., Morin S.X., Bell J.D., Taylor-Robinson S.D., Johnston D.G. Intrahepatic insulin exposure, intrahepatocellular lipid and regional body fat in nonalcoholic fatty liver disease. J. Clin. Endocrinol. Metab. 2012, 97:2151-2159.
48. Hopkins P.N., Heiss G., Ellison R.C., Province M.A., Pankow J.S., Eckfeldt J.H., Hunt S.C. Coronary artery disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia: a case-control comparison from the National Heart, Lung, and Blood Institute Family Heart Study. Circulation 2003, 108:519-523.